Pfizer Inc. (NYSE:PFE) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp boosted its position in Pfizer Inc. (NYSE:PFE) by 7.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,375,282 shares of the biopharmaceutical company’s stock after purchasing an additional 688,264 shares during the period. Stifel Financial Corp owned about 0.17% of Pfizer worth $271,321,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer during the 2nd quarter valued at approximately $29,000. Gladius Capital Management LP lifted its position in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the period. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter valued at approximately $31,000. Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the 2nd quarter valued at approximately $34,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the 3rd quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PFE shares. Citigroup began coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Stock Down 1.3 %

Shares of Pfizer stock opened at $25.23 on Thursday. The company has a fifty day moving average price of $27.60 and a 200 day moving average price of $28.42. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market cap of $142.98 billion, a price-to-earnings ratio of 34.10, a price-to-earnings-growth ratio of 0.69 and a beta of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the prior year, the company earned ($0.17) EPS. The firm’s revenue was up 31.2% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 8th were issued a $0.42 dividend. The ex-dividend date of this dividend was Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.66%. Pfizer’s dividend payout ratio is currently 227.03%.

Insiders Place Their Bets

In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.